DrugBaron
FEBRUARY 16, 2024
“There is more than one way to skin a cat” is a rather gruesome British idiom, but its sentiment surely applies to running a successful pharmaceutical portfolio. It is now more than a decade since Francesco De Rubertis, together with Kevin Johnson and Michele Olier, coined the term “asset-centric” investing to describe the approach to portfolio creation that still underpins the strategy at Medicxi.
Chemical Biology and Drug Design
FEBRUARY 15, 2024
Role of serotonin, dopamine, and norepinephrine in neural functions and symptoms involved during their altered levels. Abstract Depression is not similar to daily mood fluctuations and temporary emotional responses to day-to-day activities. Depression is not a passing problem; it is an ongoing problem. It deals with different episodes consisting of several symptoms that last for at least 2 weeks.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Science Daily: Pharmacology News
FEBRUARY 8, 2024
Researchers have uncovered the first direct evidence that the West Antarctic Ice Sheet shrunk suddenly and dramatically at the end of the Last Ice Age, around eight thousand years ago. The evidence, contained within an ice core, shows that in one location the ice sheet thinned by 450 meters -- that's more than the height of the Empire State Building -- in just under 200 years.
Nvidia Developer: Drug Discovery
FEBRUARY 28, 2024
Predicting 3D protein structures from amino acid sequences has been an important long-standing question in bioinformatics. In recent years, deep. Predicting 3D protein structures from amino acid sequences has been an important long-standing question in bioinformatics. In recent years, deep learning–based computational methods have been emerging and have shown promising results.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Broad Institute
FEBRUARY 16, 2024
Study finds youth-onset diabetes is a genetically distinct form of the disorder By Claire Hendershot February 16, 2024 Breadcrumb Home Study finds youth-onset diabetes is a genetically distinct form of the disorder Researchers suggest diabetes exists in multiple forms on a spectrum of varying genetic factors and symptoms. By Claire Hendershot February 16, 2024 Image by Ricardo Job-Reese, Broad Communications.
BioPharma Drive: Drug Pricing
FEBRUARY 2, 2024
The California biotech is the third this year to go public, following stock offerings from CG Oncology and Arrivent Biopharma.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Antidote
FEBRUARY 2, 2024
Endometrial cancer, also known as endometrial carcinoma or uterine cancer , is a condition that approximately 66,000 individuals are diagnosed with annually, and instances rise roughly 2% in the United States each year. Because it is often caught early, a person’s prognosis is typically good — but it is still a disheartening diagnosis that significantly impacts the lives of those who experience it.
Science Daily: Pharmacology News
FEBRUARY 21, 2024
Scientists introduce what they call 'simultaneous and heterogeneous multithreading' or SHMT. This system doubles computer processing speeds with existing hardware by simultaneously using graphics processing units (GPUs), hardware accelerators for artificial intelligence (AI) and machine learning (ML), or digital signal processing units to process information.
Nvidia Developer: Drug Discovery
FEBRUARY 14, 2024
The quest for new, effective treatments for diseases that remain stubbornly resistant to current therapies is at the heart of drug discovery. This traditionally. The quest for new, effective treatments for diseases that remain stubbornly resistant to current therapies is at the heart of drug discovery. This traditionally long and expensive process has been radically improved by AI techniques like deep learning, empowered by the rise of accelerated computing.
Broad Institute
FEBRUARY 19, 2024
Largest and most diverse genome-wide association study of type 2 diabetes reveals new genetic factors By Claire Hendershot February 19, 2024 Breadcrumb Home Largest and most diverse genome-wide association study of type 2 diabetes reveals new genetic factors By studying a diversity of participants, scientists find nearly 150 new locations in the genome linked to type 2 diabetes risk.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioPharma Drive: Drug Pricing
FEBRUARY 15, 2024
Analysts pressed Alnylam executives on the reasons for the changes to HELIOS-B, a Phase 3 study in ATTR amyloidosis with cardiomyopathy that is important to the company’s future.
Drugs.com
FEBRUARY 27, 2024
TUESDAY, Feb. 27, 2024 -- Eye ointment products made in India and sold in the United States at Walmart, CVS and other retailers are being recalled due to a danger of infection.Brassica Pharma Pvt. Ltd., of Maharastra, India, said it is recalling.
Codon
FEBRUARY 13, 2024
Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Read it on our website here. Illustration by David S. Goodsell, RCSB Protein Data Bank and Scripps Research. doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of u
Science Daily: Pharmacology News
FEBRUARY 15, 2024
Our brains are 'programmed' to learn more from people we like -- and less from those we dislike. This has been shown by researchers in cognitive neuroscience in a series of experiments.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Antidote
FEBRUARY 23, 2024
Individuals living with an illness are likely well-versed in the art of discussing difficult topics with their family and friends. However, for those who are considering taking part in a clinical trial, there may be extra questions to consider when sharing their intent to enroll.
Broad Institute
FEBRUARY 19, 2024
Genetic risk prediction for 10 chronic diseases moves closer to the clinic By Corie Lok February 19, 2024 Breadcrumb Home Genetic risk prediction for 10 chronic diseases moves closer to the clinic As part of a nationwide collaboration, Broad Clinical Labs researchers have optimized 10 polygenic scores for use in clinical research as part of a study on how to implement genetic risk prediction for patients.
BioPharma Drive: Drug Pricing
FEBRUARY 7, 2024
The new firm intends to carefully select its startups and fund them for the long haul. “We're not a company formation factory,” said Aaron Kantoff, the firm’s co-founder.
Drugs.com
FEBRUARY 19, 2024
MONDAY, Feb. 19, 2024 -- When settling into your senior years, you need to be especially careful when taking medicines, herbal remedies and supplements, the U.S. Food and Drug Administration says.That’s because older adults are likely to use.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Perficient: Drug Development
FEBRUARY 22, 2024
I get a lot of enjoyment from the creative and innovative side of the work I do. Helping clients or my teams break out of the day-to-day and explore the unexpected. I’ve discussed innovation myths before and how to use lateral thinking to expand your pool of ideas in unexpected ways. One of my favorite aspects is seeing how random great ideas can be!
Science Daily: Pharmacology News
FEBRUARY 8, 2024
Following the arrival of the first farmers in Scandinavia 5,900 years ago, the hunter-gatherer population was wiped out within a few generations, according to a new study. The results, which are contrary to prevailing opinion, are based on DNA analysis of skeletons and teeth found in what is now Denmark.
FDA Law Blog: Biosimilars
FEBRUARY 7, 2024
By John A. Gilbert — Last week, DEA and DOJ announced a $59 million civil penalty settlement with eBay related to the failure to comply with Controlled Substances Act (CSA) requirements for identifying purchasers, maintaining records, and filing reports of individuals selling/purchasing pill presses and encapsulating machines. As stated in the press release , this was the fourth largest civil penalty settlement under the CSA and, ironically, did not involve the sale or distribution of any contr
Broad Institute
FEBRUARY 29, 2024
Global survey of gut microbes uncovers 18 new bacterial species and clues to antibiotic resistance By Leah Eisenstadt February 29, 2024 Breadcrumb Home Global survey of gut microbes uncovers 18 new bacterial species and clues to antibiotic resistance Researchers examined scat from hundreds of animals around the world and pinpointed genes that could fuel drug-resistant infections.
BioPharma Drive: Drug Pricing
FEBRUARY 21, 2024
The full results spotlight cell therapy’s potential to treat lupus and other inflammatory conditions, but also the problems drug developers must solve first.
Drugs.com
FEBRUARY 14, 2024
WEDNESDAY, Feb. 14, 2024 -- An Oregonian who was diagnosed with the bubonic plague -- the disease that killed millions of Europeans in the Middle Ages -- probably got it from an infected pet cat, health officials said. The patient and all close.
Perficient: Drug Development
FEBRUARY 27, 2024
This time of year, I like to talk about updating the data strategy for the new year to include new business goals and new technology and in doing so I sometimes forget that there are still many companies that do not have a data strategy to update. What is a Data Strategy and why do I need one? Most organizations have multiple data management initiatives underway including master data management, data governance, data migration, data modernization, OLTP operational data cleanup, data ingestion, a
Science Daily: Pharmacology News
FEBRUARY 7, 2024
Inspired during field work in South Australia's Flinders Ranges, geoscientists have proposed that all-time low volcanic carbon dioxide emissions triggered a 57 million year-long global 'Sturtian' ice age.
Drug Target Review
FEBRUARY 2, 2024
What specific limitations in mirroring diseases in humans are commonly observed when using animal models for preclinical research? The standard animal model paradigm for drug discovery does not translate well to effects in patients for a number of reasons. For one, animal models require disease induction, either genetic or surgical modifications, diet, or application of a disease inducing agent or toxin, yet this is nothing like how diseases progress in humans, which typically take years to deve
Broad Institute
FEBRUARY 21, 2024
#WhyIScience Q&A: A software engineer develops computational tools for psychiatric and brain research By Claire Hendershot February 21, 2024 Breadcrumb Home #WhyIScience Q&A: A software engineer develops computational tools for psychiatric and brain research Khalid Shakir talks about his work analyzing large single-cell datasets, his excitement around AI, and the importance of mentorship and community in science.
BioPharma Drive: Drug Pricing
FEBRUARY 5, 2024
The pharma disclosed positive results from two studies testing its antibody drug nipocalimab in generalized myasthenia gravis or Sjögren's disease.
Drugs.com
FEBRUARY 13, 2024
TUESDAY, Feb. 13, 2024 -- Mammograms are a lifesaving misery for middle-aged women, but a new tool could make getting a breast cancer screening as easy as spitting.Literally.A new hand-held biosensor can detect breast cancer biomarkers from a tiny.
Perficient: Drug Development
FEBRUARY 14, 2024
Revolutionizing B2C Commerce: The Impact of Generative AI In the dynamic landscape of commerce and consumer-driven markets, Business-to-Consumer (B2C) organizations are increasingly turning to generative AI to revolutionize their operations and enhance customer experiences. Generative AI, a subset of artificial intelligence, empowers these organizations to create content, personalize interactions, and optimize various aspects of their business processes.
Science Daily: Pharmacology News
FEBRUARY 5, 2024
The Circumpolar Current works as a regulator of the planet's climate. Its origins were thought to have caused the formation of the permanent ice in Antarctica about 34 million years ago. Now, a study has cast doubt on this theory, and has changed the understanding of how the ice sheet in Antarctic developed in the past, and what this could mean in the future as the planet's climate changes.
FDA Law Blog: Biosimilars
FEBRUARY 2, 2024
By Steven J. Gonzalez & Allyson B. Mullen — On January 31, 2024, FDA announced its intent to initiate the reclassification process for most in vitro diagnostic (IVD) products that are currently class III (high risk) into class II (moderate risk). Most of these reclassified tests will supposedly be infectious disease and companion diagnostic IVDs.
Expert insights. Personalized for you.
355 
Let's personalize your content